BARALDI, CARLO
 Distribuzione geografica
Continente #
EU - Europa 8.948
NA - Nord America 5.198
AS - Asia 2.506
SA - Sud America 406
AF - Africa 67
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.162
Nazione #
IT - Italia 6.480
US - Stati Uniti d'America 5.076
GB - Regno Unito 1.014
SG - Singapore 814
CN - Cina 547
VN - Vietnam 316
HK - Hong Kong 310
BR - Brasile 303
FR - Francia 273
SE - Svezia 194
DE - Germania 187
NL - Olanda 169
RU - Federazione Russa 127
IN - India 82
KR - Corea 74
CH - Svizzera 73
UA - Ucraina 70
FI - Finlandia 66
TR - Turchia 64
ID - Indonesia 59
MX - Messico 51
CA - Canada 47
ES - Italia 45
JP - Giappone 45
PL - Polonia 42
AR - Argentina 40
BG - Bulgaria 40
IE - Irlanda 35
BD - Bangladesh 32
AU - Australia 31
ZA - Sudafrica 21
IQ - Iraq 19
AE - Emirati Arabi Uniti 17
EC - Ecuador 17
EG - Egitto 17
IR - Iran 17
BE - Belgio 16
PK - Pakistan 16
AT - Austria 15
TW - Taiwan 15
PH - Filippine 14
CO - Colombia 13
NO - Norvegia 11
DK - Danimarca 10
MY - Malesia 10
CZ - Repubblica Ceca 9
HU - Ungheria 9
LT - Lituania 9
CL - Cile 8
CR - Costa Rica 8
GR - Grecia 8
AL - Albania 7
IL - Israele 7
JO - Giordania 7
PT - Portogallo 7
DZ - Algeria 6
NP - Nepal 6
PY - Paraguay 6
TN - Tunisia 6
UY - Uruguay 6
BY - Bielorussia 5
KG - Kirghizistan 5
MA - Marocco 5
PE - Perù 5
UZ - Uzbekistan 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
KE - Kenya 4
RS - Serbia 4
SA - Arabia Saudita 4
EE - Estonia 3
EU - Europa 3
GE - Georgia 3
HR - Croazia 3
JM - Giamaica 3
MD - Moldavia 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AM - Armenia 2
CU - Cuba 2
GT - Guatemala 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
MT - Malta 2
OM - Oman 2
SI - Slovenia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
GY - Guiana 1
IS - Islanda 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
Totale 17.149
Città #
Southend 725
Ashburn 641
Milan 597
Singapore 511
Fairfield 507
Santa Clara 469
Rome 388
Chandler 315
Hong Kong 299
Woodbridge 252
Seattle 215
Houston 212
San Jose 191
Cambridge 178
Wilmington 164
Naples 146
Modena 142
Hefei 126
London 124
Beijing 119
Nyköping 119
Turin 116
Ho Chi Minh City 102
Bologna 97
Florence 93
Los Angeles 89
Council Bluffs 87
Ann Arbor 86
Dearborn 82
The Dalles 78
Chicago 76
Hanoi 73
New York 71
Seoul 59
Catania 56
Genoa 56
Palermo 53
Jacksonville 51
Helsinki 50
Lauterbourg 48
Bari 47
Jakarta 47
Verona 47
Parma 46
Moscow 42
San Diego 42
Pescara 39
Cagliari 35
Shanghai 34
Dallas 32
Princeton 32
São Paulo 32
Sofia 31
Salt Lake City 28
Zurich 28
Orem 25
Redwood City 25
Tokyo 25
Mexico City 24
Como 23
Munich 23
Warsaw 23
Buffalo 22
Amsterdam 21
Eugene 21
Brescia 20
Frankfurt am Main 20
L’Aquila 20
Dublin 19
Elk Grove Village 19
Chennai 18
Fremont 18
Messina 18
Paris 18
Atlanta 17
Padova 17
Ventimiglia 17
Bergamo 16
Dalmine 16
Monza 16
Phoenix 16
Tampa 16
Brasília 15
Bremen 15
Da Nang 15
Haiphong 15
Manchester 15
Perugia 15
Philadelphia 15
Reggio Emilia 15
Boston 14
Düsseldorf 14
Lucca 14
Toronto 14
Trento 14
Dong Ket 13
Istanbul 13
Rio de Janeiro 13
Ancona 12
Dolianova 12
Totale 9.211
Nome #
Correlazione tra fumo di cannabis e pneumotorace spontaneo. 6.840
Allopregnanolone serum levels in female migraineurs 783
Seizures of illicit substances for personal use in two Italian provinces: analysis of trends by type and purity from 2008 to 2017 665
Development and validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analyses of triptans in hair 506
Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study 418
Medication overuse and chronic migraine: a critical review according to clinical pharmacology 393
Monitoring of adherence to headache treatments by means of hair analysis 391
Hair testing in clinical setting: simultaneous determination of 50 psychoactive drugs and metabolites in headache patients by LC tandem MS 378
Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study 355
Diagnostic accuracy of hair analysis for the detection of triptan overuse in migraineurs 338
A case-control study of visually evoked postural responses in childhood with primary headaches 303
Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache 298
Intrapatient variability of the hair levels of pain medications in chronic migraine patients - a pilot study 277
Polypharmacy Among Headache Patients: A Cross-Sectional Study 258
Secondary spontaneous pneumothorax and bullous lung disease in cannabis and tobacco smokers. A case-control study. 256
Glutamate receptor antagonists with the potential for migraine treatment 251
Proteomic serum profile in menstrual-related and post menopause migraine 245
Melanocortin receptor agonist NDP-α-MSH improves cognitive deficits and microgliosis but not amyloidosis in advanced stages of AD progression in 5XFAD and 3xTg mice 242
Hair testing as a marker of adherence to headache treatments 242
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review 236
Serum changes of apolipoproteins in Medication Overuse Headache (MOH) 231
Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study 230
Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age 225
Erenumab per il trattamento preventivo dell'emicrania cronica: efficacia e sicurezza fino a un anno, predittori di risposta ed effetti della sospensione. 220
Anti-CGRP monoclonal antibodies improve cognitive function in patients affected by chronic migraine complicated with medication overuse-headache 218
Proteomic serum profile of female migraineurs 208
Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study 208
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study 198
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data 180
Visually Evoked Postural Responses (VEPRs) in Children with Vestibular Migraine 179
Occlusal splint therapy in patients with Ménière’s disease and temporomandibular joint disorder 170
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic 168
Topical Cannabidiol in the Treatment of digital ulcers in patients with Scleroderma: comparative Analysis and Literature Review 165
OnabotulinumtoxinA: Still the Present for Chronic Migraine 152
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 151
Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population 146
Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study 144
Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study 131
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study 105
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study 104
Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study (Acta Neurologica Belgica, (2023), 123, 3, (1039-1047), 10.1007/s13760-023-02190-5) 97
Totale 17.305
Categoria #
all - tutte 46.327
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.327


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021358 0 0 0 0 0 0 0 0 0 0 250 108
2021/20221.367 123 64 114 138 48 79 64 116 127 117 220 157
2022/20232.537 166 191 187 224 189 230 188 229 305 139 252 237
2023/20242.547 212 213 227 207 265 193 238 221 160 185 225 201
2024/20253.140 178 151 145 267 432 385 259 206 333 195 279 310
2025/20263.783 332 170 260 540 751 247 506 196 362 369 50 0
Totale 17.305